Aptevo Therapeutics (APVO, Financial) has introduced APVO455, a new preclinical candidate, to its expanding lineup of CD3-directed molecules. This addition is part of a strategy utilizing the CRIS-7 derived CD3 binding domain, which has shown significant promise for treating both blood cancers and solid tumors. Aptevo’s portfolio now includes three CD3-engaging molecules, all characterized by a low cytokine release profile.
The latest entrant, APVO455, along with APVO442, features optimized CD3 binding domains specifically designed for effective targeting of solid tumors. Each of these molecules aims to stimulate tumor-specific immune responses while reducing systemic toxicity. The suite comprises Mipletamig, which is currently in a Phase 1b/2 trial for treating acute myeloid leukemia (AML). This candidate has shown an 85% remission rate in frontline AML patients when combined with standard therapies, without evidence of cytokine release syndrome in initial trial phases.
Additionally, APVO442, focusing on prostate cancer, is in preclinical stages. APVO455 targets multiple solid tumors, further diversifying Aptevo's innovative therapeutic approaches.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Aptevo Therapeutics Inc (APVO, Financial) is $420.00 with a high estimate of $420.00 and a low estimate of $420.00. The average target implies an upside of 8,087.13% from the current price of $5.13. More detailed estimate data can be found on the Aptevo Therapeutics Inc (APVO) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Aptevo Therapeutics Inc's (APVO, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
